Worldwide Biological Safety Testing Industry to 2027 - Featuring Avance Biosciences, Creative Biogene and Eurofins Scientific Among Others

News provided by

Apr 07, 2022, 13:45 ET

DUBLIN, April 7, 2022 /PRNewswire/ -- The "Biological Safety Testing Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.

The global biological safety testing market reached a value of US$ 3.51 Billion in 2021. Looking forward, the publisher expects the market to reach US$ 7.16 Billion by 2027, exhibiting at a CAGR of 12.55% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.

Biopharmaceutical products are widely used in the diagnosis, prevention, and treatment of various diseases. However, their manufacturing process and the complex structural and biological characteristics pose several safety concerns. Therefore, health agencies of numerous countries have mandated a thorough biological safety testing on these products. Biological safety testing ensures products are free from contaminants before a clinical investigation takes place. Nowadays, several companies are providing comprehensive biological safety testing packages that are compliant with global stringent safety standards.

Biological Safety Testing Market Trends:

The coronavirus disease (COVID-19) outbreak and the urgent need for a potential treatment are among the key factors positively influencing the demand for biological safety testing worldwide. It evaluates the safety of candidate vaccines prior to their dispatch to manufacturers. Moreover, the escalating demand for biopharmaceutical products on account of the rising prevalence of targeted diseases and the easy access to healthcare services is fueling the market growth. Additionally, the rising number of novel drugs and biological products at clinical trials is contributing to the market growth.

Apart from this, biological products derived from mammalian cell lines pose an inherent risk for microbial and viral contaminants. This is increasing the adoption of stringent safety testing to ensure biologic materials are safe and free of contaminants during the entire development process.

Furthermore, due to the rising utilization of single-use medical items, pharmaceutical manufacturers are focusing on producing safe products and achieving sterility assurance, which, in turn, is driving the market. Besides this, market leaders are forming strategic partnerships with major research organizations to provide drug discovery and development services and produce cost-efficient and technologically advanced testing methods. This is anticipated to create a positive outlook for the market.

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Avance Biosciences, Charles River Laboratories, Creative Biogene, Eurofins Scientific, Lonza Group AG, Maravai LifeSciences, Pace Analytical Services Inc., Pacific BioLabs, Sartorius AG, SGS SA, ViruSure GmbH (Asahi Kasei Corporation) and WuXi Biologics.

Key Questions Answered in This Report:

How has the global biological safety testing market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global biological safety testing market?
What are the key regional markets?
What is the breakup of the market based on the product and services?
What is the breakup of the market based on the test type?
What is the breakup of the market based on the application?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global biological safety testing market and who are the key players?
What is the degree of competition in the industry?

Key Topics Covered:

1 Preface

2 Scope and Methodology

3 Executive Summary

4 Introduction
4.1 Overview
4.2 Key Industry Trends

5 Global Biological Safety Testing Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Product and Services
6.1 Kits and Reagents
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Instruments
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Services
6.3.1 Market Trends
6.3.2 Market Forecast

7 Market Breakup by Test Type
7.1 Endotoxin Tests
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Sterility Tests
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Cell Line Authentication and Characterization Tests
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Bioburden Tests
7.4.1 Market Trends
7.4.2 Market Forecast
7.5 Residual Host Contaminant Detection Tests
7.5.1 Market Trends
7.5.2 Market Forecast
7.6 Adventitious Agent Detection Tests
7.6.1 Market Trends
7.6.2 Market Forecast
7.7 Others
7.7.1 Market Trends
7.7.2 Market Forecast

8 Market Breakup by Application
8.1 Vaccine Development
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Blood Products Testing
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Cellular and Gene Therapy
8.3.1 Market Trends
8.3.2 Market Forecast
8.4 Tissue and Tissue-related Products Testing
8.4.1 Market Trends
8.4.2 Market Forecast
8.5 Stem Cell Research
8.5.1 Market Trends
8.5.2 Market Forecast

9 Market Breakup by Region

10 SWOT Analysis

11 Value Chain Analysis

12 Porters Five Forces Analysis

13 Price Analysis

14 Competitive Landscape
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
14.3.1 Avance Biosciences
14.3.1.1 Company Overview
14.3.1.2 Product Portfolio
14.3.1.3 SWOT Analysis
14.3.2 Charles River Laboratories
14.3.2.1 Company Overview
14.3.2.2 Product Portfolio
14.3.2.3 SWOT Analysis
14.3.3 Creative Biogene
14.3.3.1 Company Overview
14.3.3.2 Product Portfolio
14.3.3.3 SWOT Analysis
14.3.4 Eurofins Scientific
14.3.4.1 Company Overview
14.3.4.2 Product Portfolio
14.3.4.3 SWOT Analysis
14.3.5 Lonza Group AG
14.3.5.1 Company Overview
14.3.5.2 Product Portfolio
14.3.5.3 SWOT Analysis
14.3.6 Maravai LifeSciences
14.3.6.1 Company Overview
14.3.6.2 Product Portfolio
14.3.6.3 SWOT Analysis
14.3.7 Pace Analytical Services Inc.
14.3.7.1 Company Overview
14.3.7.2 Product Portfolio
14.3.7.3 SWOT Analysis
14.3.8 Pacific BioLabs
14.3.8.1 Company Overview
14.3.8.2 Product Portfolio
14.3.8.3 SWOT Analysis
14.3.9 Sartorius AG
14.3.9.1 Company Overview
14.3.9.2 Product Portfolio
14.3.9.3 SWOT Analysis
14.3.10 SGS SA
14.3.10.1 Company Overview
14.3.10.2 Product Portfolio
14.3.10.3 SWOT Analysis
14.3.11 ViruSure GmbH (Asahi Kasei Corporation)
14.3.11.1 Company Overview
14.3.11.2 Product Portfolio
14.3.11.3 SWOT Analysis
14.3.12 WuXi Biologics
14.3.12.1 Company Overview
14.3.12.2 Product Portfolio
14.3.12.3 SWOT Analysis

For more information about this report visit https://www.researchandmarkets.com/r/cov4mp